HotAvitag
Biotinylated Human LILRB2 / CD85d / ILT4 Protein, His,Avitag™ (MALS verified)Cat. No. LI2-H82E7
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| LILRB2 | HOTAvitag LI2-H82E7 | Biotinylated Human LILRB2 / CD85d / ILT4 Protein, His,Avitag™ (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $380.00 25ug | ||
| LILRB2 | HOT LI2-H5220 | Human LILRB2 / CD85d / ILT4 Protein, His Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $310.00 100ug | ||
| LILRB2 | HOTAvitag LI2-H82F5 | Biotinylated Human LILRB2 / CD85d / ILT4 Protein, Fc,Avitag™ (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $380.00 25ug | ||
| LILRB2 | HOT LI2-H5253 | Human LILRB2 / CD85d / ILT4 Protein, Fc Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $310.00 100ug | ||
| LILRB2 | Cynomolgus LILRB2 / CD85d / ILT4 Protein, His Tag | Cynomolgus | HEK293 | ![]() | SDS-PAGE | $270.00 100ug | |||
| LILRB2 | Avitag LI2-C82E3 | Biotinylated Cynomolgus LILRB2 / CD85d / ILT4 Protein, His,Avitag™ | Cynomolgus | HEK293 | ![]() | SDS-PAGE | $360.00 25ug |
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| LILRB2 mAb - 01 | PCC | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Polzastobart | JTX-8064 | Phase 2 Clinical | Jounce Therapeutics Inc | Neoplasms | Details |
| IO-108 | IO-108 | Phase 2 Clinical | Yiming Biomedical Technology (Hangzhou) Co Ltd | Liver Neoplasms; Solid tumours | Details |
| MK-4830 | MK-4830 | Phase 2 Clinical | Agenus Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Ovarian Neoplasms; Solid tumours | Details |
| SPX-303 | SPX-303 | Phase 2 Clinical | SparX Biopharmaceutical Corp | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| OR-502 | OR502; OR-502 | Phase 2 Clinical | OncoResponse Inc | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Skin Melanoma; Solid tumours | Details |
| NGM-707 | NGM-707 | Phase 2 Clinical | Merck & Co, NGM Biopharmaceuticals Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Glioblastoma; Melanoma; Mesothelioma; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| AK-150 (Akeso) | AK150; AK-150 | Phase 1 Clinical | Solid tumours | Details | |
| CHS-1000 | CHS-1000 | Phase 1 Clinical | Coherus Biosciences Inc | Solid tumours | Details |
| BMS-986406 | BMS-986406; ONO-7226 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| CDX-585 | CDX-585; BSI-585 | Phase 1 Clinical | Biosion Inc, Celldex Therapeutics | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| ES-009 | ES-009 | Phase 1 Clinical | Elpiscience (Shanghai) Biopharma Ltd | Neoplasms; Solid tumours | Details |